Earlier this year, a report from Pharmaceutical Executive detailed the ways in which China is becoming an essential R&D partner for pharma and biotech companies. Pharmaceutical Executive spoke with John Standford, executive director of Incubate, about the rise of China as an R&D partner and the US government’s responses. Pharmaceutical Executive: How can regulators and the industry work together to improve the US pharma ecosystem? The reason the UK is so bullish on becoming a future center of drug development is precisely because they have that data centralized. It's less satisfying as a soundbite, but it is exactly what the biotech industry needs, and it is what biotech investors absolutely want to see.